No cytotoxic peptide is FDA approved for cancer, but several peptide-based oncology drugs are. Here's what FDA-approved anticancer peptides really include.
No FDA-approved anticancer peptide kills tumor cells directly the way chemotherapy does. The peptide-based cancer drugs that carry FDA approval work through hormone suppression, receptor targeting, or proteasome inhibition, and every one of them requires a prescription. "FDA-approved anticancer peptides" is therefore a short, specific list, not the long catalog of research peptides promoted online.
What Counts as an Anticancer Peptide?
In pharmacology, a peptide is a short chain of amino acids, generally fewer than 50 residues. Longer chains are classified as proteins, which is why antibodies and enzymes are not usually grouped with peptides.
Scientists use the term "anticancer peptide" in two different ways, and that difference explains most of the confusion:
- Cytotoxic anticancer peptides: short peptides that bind cancer cell membranes or mitochondria and kill tumor cells directly. None are FDA approved for human use.
- Peptide-based cancer drugs: peptides that act on hormone receptors, somatostatin receptors, or the proteasome. Several are FDA approved and used in oncology every day.
Headlines about "anticancer peptides" almost always describe the first group, which is still experimental. That is why patients who search for approved products find so little.
FDA-Approved Peptide-Based Cancer Drugs
These medicines are peptides, peptide derivatives, or radiolabeled peptides with an approved oncology indication in the United States.
| Generic name | Brand example | Peptide class | Approved cancer use |
|---|---|---|---|
| Leuprolide | Lupron Depot, Eligard | GnRH agonist nonapeptide | Prostate cancer |
| Goserelin | Zoladex | GnRH agonist decapeptide | Prostate cancer, breast cancer |
| Triptorelin | Trelstar | GnRH agonist | Advanced prostate cancer |
| Degarelix | Firmagon | GnRH antagonist | Advanced prostate cancer |
| Histrelin | Vantas | GnRH agonist | Advanced prostate cancer |
| Octreotide | Sandostatin | Somatostatin analog octapeptide | Carcinoid tumors, VIPoma |
| Lanreotide | Somatuline Depot | Somatostatin analog | Gastroenteropancreatic neuroendocrine tumors |
| Lutetium Lu 177 dotatate | Lutathera | Radiolabeled somatostatin peptide | Gastroenteropancreatic neuroendocrine tumors |
| Bortezomib | Velcade | Dipeptide boronate proteasome inhibitor | Multiple myeloma, mantle cell lymphoma |
| Carfilzomib | Kyprolis | Tetrapeptide epoxyketone | Multiple myeloma |
| Ixazomib | Ninlaro | Tripeptide boronate | Multiple myeloma |
Leuprolide, goserelin, triptorelin, degarelix, and histrelin are FDA-approved peptide drugs used in cancer care, and all five work by interrupting the hormonal signals that feed prostate or breast tumors. Bortezomib, carfilzomib, and ixazomib are peptide-derived proteasome inhibitors that treat multiple myeloma by blocking a protein-recycling system cancer cells depend on.
Lutathera is the only FDA-approved radiolabeled peptide therapy. It delivers radiation directly to somatostatin receptor-positive neuroendocrine tumors, a genuinely different mechanism from traditional chemotherapy.
Why Direct-Acting Anticancer Peptides Are Not Approved Yet
Peptides that destroy cancer cells in a laboratory dish often fail in the human body. Blood enzymes degrade them within minutes, they penetrate solid tumors poorly, and they can damage healthy cell membranes that resemble cancer membranes.
Researchers are testing several workarounds: PEGylation to extend half-life, D-amino acids and stapled peptides to resist breakdown, and peptide-drug conjugates that carry a toxin to a tumor receptor. These approaches are promising, but none has yet produced an FDA-approved cytotoxic anticancer peptide.
Pepaxto (melphalan flufenamide) is a useful cautionary example. It is a peptide-drug conjugate that received accelerated approval in 2021 for multiple myeloma, then was withdrawn from the US market in 2022 after a confirmatory trial showed worse overall survival. Accelerated approval is not the same as proven benefit.
Peptides Often Mistaken for Approved Cancer Drugs
Online interest in peptides is dominated by products that are not cancer drugs at all. If you review all peptides that are fda approved, you will notice that the names promoted most heavily on social media, including BPC-157, TB-500, AOD-9604, CJC-1295, and ipamorelin, do not appear on any of those lists.
Knowing what peptides are not fda approved is just as important as knowing which ones are. None of the following has FDA approval for human use in the United States:
- BPC-157: studied in animals for tendon and gut healing; no approved human indication.
- TB-500: a thymosin beta-4 fragment sold for research use only.
- AOD-9604: a modified growth hormone fragment studied for fat loss. If you have asked is aod-9604 fda approved, the answer is no; it is not approved for weight loss, cancer, or any other condition.
- CJC-1295 and ipamorelin: growth hormone secretagogues with no approved human use, separately or together.
These compounds are typically sold as "research chemicals" or labeled "not for human consumption." That label is a legal disclaimer, not a statement of safety.
How to Verify a Peptide's FDA Approval Status
- Search Drugs@FDA or the Orange Book using the generic name.
- Check DailyMed for the current FDA-approved package insert.
- Confirm that an NDA or BLA number exists for the product.
- Read the approved indication, because approval for one cancer type does not extend to others.
If you are looking for a list of fda-approved peptides pdf, note that the FDA does not publish a peptide-specific document. The Orange Book is the official, searchable record, and it is updated monthly.
Patients also ask where to buy fda-approved peptides. Approved peptide drugs are dispensed through licensed US pharmacies after a prescription from a clinician, never through research-chemical websites, overseas sellers, or social media vendors.
Safety and Questions to Ask Your Oncologist
Every FDA-approved peptide cancer drug carries meaningful side effects. GnRH agonists cause hot flashes, fatigue, and bone loss; somatostatin analogs cause gastrointestinal upset and gallstones; proteasome inhibitors cause peripheral neuropathy and low blood counts.
Most peptide cancer drugs require refrigeration and injection under clinical supervision. Compounded or research-grade versions sold online are not reviewed for purity, sterility, or dose accuracy.
Before starting any peptide therapy, ask your care team:
- Is this peptide FDA approved for my specific cancer type and stage?
- What do randomized trials show, rather than early-phase or animal studies?
- Which side effects should I report immediately?
- Are there non-peptide options with stronger evidence?
No anticancer peptide, approved or experimental, replaces standard treatment unless a clinical trial demonstrates that it does. Anyone marketing a peptide as a stand-alone cancer cure is making a claim the FDA has not reviewed. The real landscape of FDA-approved anticancer peptides is small, well documented, and prescription-only.
Frequently Asked Questions
Are there any FDA-approved anticancer peptides?
No peptide that directly kills cancer cells is FDA approved for human use in the United States. The peptide-based cancer drugs that are approved, including leuprolide, octreotide, Lutathera, and bortezomib, work by suppressing hormones, targeting somatostatin receptors, or blocking the proteasome. Direct-acting cytotoxic anticancer peptides remain experimental and are studied only in clinical trials.
Is AOD-9604 FDA approved?
No. AOD-9604 is a modified fragment of human growth hormone that has been studied for obesity, and it holds no FDA approval for weight loss, cancer, or any other indication. In the US it is sold only as a research chemical, which means it has not been reviewed for safety, purity, or strength for human use.
Is CJC-1295/ipamorelin FDA approved?
No. Neither CJC-1295 nor ipamorelin is FDA approved for human use, alone or in combination. Both are growth hormone-releasing peptides sold online as research chemicals, and neither has any role in FDA-approved cancer treatment.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.